Dr. Yiwei Qi
M.D., Ph.D.
Dr. Yiwei Qi received his Doctor of Medicine (M.D.) and Ph.D. degrees from Tongji Medical College, Huazhong University of Science and Technology. His research primarily focuses on glioma, neurodegenerative diseases and traumatic brain injury.
Currently, Dr. Qi is working at the German Cancer Research Center (DKFZ), focusing on the construction of glioma organoid models and exploring personalized treatment strategies.
From 2022 to 2024, Dr. Qi served as a neurosurgeon at the Department of Neurosurgery, Tongji Hospital. His clinical and research interests during this time included liquid biopsy for gliomas, traumatic brain injury, and neural damage caused by glial scarring.
From 2019 to 2022, Dr. Qi conducted postdoctoral research at Tongji Hospital, where he specialized in glioma immunology and immunotherapy. During this period, he identified a novel complex involved in the regulation of glioma immune response and immune evasion and elucidated its potential regulatory mechanisms. He also explored a tumor vaccine based on dendritic cells and cytokine-induced killer (DC-CIK) cells targeting glioma neoantigens. The clinical trial that confirmed both the safety and preliminary efficacy of this vaccine approach.
Dr. Qi has published multiple peer-reviewed articles as first author or co-corresponding author, with a cumulative impact factor exceeding 30 and over 170 citations to date.
Dr. Yiwei Qi
M.D., Ph.D.
Dr. Yiwei Qi received his Doctor of Medicine (M.D.) and Ph.D. degrees from Tongji Medical College, Huazhong University of Science and Technology. His research primarily focuses on glioma, neurodegenerative diseases and traumatic brain injury.
Currently, Dr. Qi is working at the German Cancer Research Center (DKFZ), focusing on the construction of glioma organoid models and exploring personalized treatment strategies.
From 2022 to 2024, Dr. Qi served as a neurosurgeon at the Department of Neurosurgery, Tongji Hospital. His clinical and research interests during this time included liquid biopsy for gliomas, traumatic brain injury, and neural damage caused by glial scarring.
From 2019 to 2022, Dr. Qi conducted postdoctoral research at Tongji Hospital, where he specialized in glioma immunology and immunotherapy. During this period, he identified a novel complex involved in the regulation of glioma immune response and immune evasion and elucidated its potential regulatory mechanisms. He also explored a tumor vaccine based on dendritic cells and cytokine-induced killer (DC-CIK) cells targeting glioma neoantigens. The clinical trial that confirmed both the safety and preliminary efficacy of this vaccine approach.
Dr. Qi has published multiple peer-reviewed articles as first author or co-corresponding author, with a cumulative impact factor exceeding 30 and over 170 citations to date.